This site is intended for Great Britain healthcare professionals only
Menu
Close
Menu
Close
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
 |
Cibinqo is a Janus kinase (JAK)1 inhibitor.1 |
 |
JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cell surface to influence haematopoiesis and immune cell function.1 |
 |
JAKs phosphorylate and activate STATs, which in turn modulate activity in the cell. Inhibition of JAK1 interrupts signalling pathways by preventing the phosphorylation and activation of STATs.1 |
 |
 |
INFLAMMATION2,7IL-4 and IL-13 are important mediators of type 2 inflammation and are major drivers of atopic inflammation. |
 |
 |
ITCH2,4,6IL-31 is a type 2 inflammatory cytokine that plays a role in mediating itch and atopic inflammation. |
 |
 |
BARRIER DISRUPTION2,4IL-22 helps induce epidermal hyperplasia and skin barrier disruption in AD. |
In addition to the roles of the cytokines described here, these, and other cytokines are believed to play multiple roles in AD pathophysiology.8,9
The JAK/STAT pathway is believed to be an important mediator of the pathophysiology of atopic dermatitis.11 JAKs are a family of intracellular cytoplasmic protein tyrosine kinases that are associated with cytokine and growth factor receptor subunits.2,3,10–12
Upon binding of proinflammatory cytokines, cytokine receptors dimerise, bringing JAK pairs into close proximity.2,3,10–12
The paired JAKs then phosphorylate and activate each other.2,3,10–12
JAK-mediated phosphorylation of the cytokine receptor creates a binding site for STATs.2,3,10–12
STATs are recruited and phosphorylated by activated JAKs.2,3,10–12
Activated STAT dimers move into the nucleus resulting in increased transcription of proinflammatory cytokine genes.2,3,10–12
Cibinqo has been studied across six Phase III trials as monotherapy or in combination with medicated topical therapies.1–7
3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.
References:
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2021 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
Add indication message here. It can link a link,
and you can EMBOLDEN text
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd.
Pfizer accepts no responsibility for the content or services of the linked site.
PP-PFE-GBR-3858. November 2021
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.
Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to Pfizer medicines or
business which it has provided or reviewed.
PP-PFE-GBR-3859. November 2021